IJSRP, Volume 2, Issue 11, November 2012 Edition [ISSN 2250-3153]
Betsy Varughese, Rajesh Kumar , Neerja Bhatla , S.N Dwivedi , Manoj Dhingra, Renu Dhingra
The present study is aimed to ascertain whether preeclampsia is associated with changes in serum levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and soluble fms-like tyrosine kinase -1 (sFlt-1) and urinary excretion levels of PlGF in Indian patients. Serum and urine samples were obtained from 40 women with preeclampsia and 40 normotensive, non-proteinuric pregnant women as control and the levels of these factors were analyzed using enzyme-linked immunosorbent assay (ELISA). The serum levels of VEGF (mean ± SD 170.53 ± 36.56 Vs 254.61 ± 47.394 pg/ml, p<0.0001), PlGF (mean ± SD 236.77 ± 93.70 Vs 744.98 ± 168.55 pg/ml, p<0.0001) and the urinary levels of PlGF (mean ± SD 30.08 ± 9.42 Vs 77.70 ± 24.70 pg/ml, p<0.0001) were significantly lower (mean ± SD 236.77 ± 93.70 Vs 744.98 ± 168.55 pg/ml, p<0.0001) where as serum levels of sFlt-1 were significantly higher (median 11295.25 Vs 2936.2 pg/ml, p<0.0001) in preeclamptic patients compared to the control. In conclusion, preeclampsia is associated with alterations in serum and urine angiogenic factors. The longitudinal measurement of these angiogenic factors in serum might be ideal for ascertaining the risk of preeclampsia, but measuring the levels of PlGF in the urine during routine antenatal care could be a simpler and noninvasive factor, if it can be used as definite, informative screening marker for preeclampsia.